Immunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have been assigned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $70.62.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upgraded shares of Immunocore from a “neutral” rating to an “overweight” rating and set a $22.00 price target for the company in a report on Wednesday, September 13th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Immunocore in a research note on Wednesday, August 23rd. Needham & Company LLC started coverage on Immunocore in a research report on Wednesday, September 13th. They set a “buy” rating and a $75.00 price objective for the company. Canaccord Genuity Group started coverage on Immunocore in a research note on Monday, July 17th. They issued a “hold” rating and a $67.00 target price on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $79.00 price target on shares of Immunocore in a research report on Monday, July 31st.

Institutional Trading of Immunocore

A number of large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in shares of Immunocore by 56.8% during the 1st quarter. Wellington Management Group LLP now owns 3,375,309 shares of the company’s stock worth $166,875,000 after acquiring an additional 1,222,343 shares during the period. Fiera Capital Corp acquired a new position in Immunocore in the 2nd quarter valued at $31,257,000. Braidwell LP bought a new position in Immunocore during the 1st quarter worth $21,067,000. Pictet Asset Management SA lifted its holdings in shares of Immunocore by 43.8% during the first quarter. Pictet Asset Management SA now owns 888,951 shares of the company’s stock worth $43,950,000 after buying an additional 270,636 shares in the last quarter. Finally, Great Point Partners LLC bought a new stake in shares of Immunocore in the first quarter valued at about $12,625,000. Institutional investors and hedge funds own 73.45% of the company’s stock.

Immunocore Stock Performance

Shares of Immunocore stock opened at $52.79 on Monday. The stock’s fifty day simple moving average is $60.60 and its 200 day simple moving average is $57.41. The company has a current ratio of 4.28, a quick ratio of 4.26 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $2.58 billion, a PE ratio of -40.92 and a beta of 0.67. Immunocore has a 12 month low of $41.25 and a 12 month high of $69.06.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.03. Immunocore had a negative return on equity of 17.97% and a negative net margin of 27.72%. The business had revenue of $60.70 million for the quarter, compared to analysts’ expectations of $59.39 million. On average, research analysts predict that Immunocore will post -1.4 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers.